ArticleEuropean journal of pediatrics2015
Multiple consecutive norovirus infections in the first 2 years of life.
Article in European journal of pediatrics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Characterization of humoral and cellular immunity induced by mRNA vaccines expressing norovirus VP1 proteins in mice and NHPs.Molecular therapy : the journal of the American Society of Gene Therapy · 2026Article
- A narrative review of norovirus epidemiology, biology, and challenges to vaccine development.NPJ vaccines · 2024Review
- Norovirus Protease Structure and Antivirals Development.Viruses · 2021Review
- Serological Humoral Immunity Following Natural Infection of Children with High Burden Gastrointestinal Viruses.Viruses · 2021Review
- Humoral and Mucosal Immune Responses to Human Norovirus in the Elderly.The Journal of infectious diseases · 2020Article
- Article
- Rotavirus VP6 as an Adjuvant for Bivalent Norovirus Vaccine Produced inPharmaceutics · 2019Article
- Development of T cell immunity to norovirus and rotavirus in children under five years of age.Scientific reports · 2019Article
- Identification of a First Human Norovirus CD8Frontiers in immunology · 2018Article
- Prospects and Challenges in the Development of a Norovirus Vaccine.Clinical therapeutics · 2017Review
- Static and Evolving Norovirus Genotypes: Implications for Epidemiology and Immunity.PLoS pathogens · 2017Article
- Norovirus vaccines: Correlates of protection, challenges and limitations.Human vaccines & immunotherapeutics · 2016Review
- Norovirus-Specific Memory T Cell Responses in Adult Human Donors.Frontiers in microbiology · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Studies investigating the magnitude and breath of protective immune responses after primary and subsequent norovirus infections in pediatric populations are limited. We investigated incidence of norovirus infections and serological responses in a child from longitudinal stool and serum samples collected from birth to 2 years of age. Four consecutive infections with distinct genotypes of norovirus were detected. Serum antibodies were genotype-specific offering no protection to reinfection with heterologous virus.
conclusionThis study describes norovirus-specific serological responses in a child with four consecutive norovirus infection during the first 2 years of life. The response is type-specific and does not protect from a subsequent infection with a heterologous virus. WHAT IS KNOWN: • Correlates of protection to norovirus infection and disease are not yet determined, and most of the presently available data concern adult population. WHAT IS NEW: • This manuscript describes serological immune responses after primary and subsequent infections in a child during the first 2 years of life.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.